The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents

Journal of Neuroimmunology

Volumn 108, Issue 1-2, 2000, Pages 136-146

  Dinter, Harald ^a   Tse, Jenny ^a   Halks Miller, Meredith ^a   Asarnow, David ^a   Onuffer, James ^a   Faulds, Daryl ^a   Mitrovic, Branislava ^a   Kirsch, Gerald ^b   Laurent, Henry ^b   Esperling, Peter ^b   Seidelmann, Dieter ^b   Ottow, Eckhard ^b   Schneider, Herbert ^b   Tuohy, Vincent K ^c   Wachtel, Helmut ^b   Perez, H Daniel ^a  

^a BAYER AG   (Germany)

^b BAYER PHARMA AG   (Germany)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Experimental autoimmune encephalomyelitis; Multiple sclerosis; Phosphodiesterase inhibitor

Indexed keywords

MESOPRAM; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GUINEA PIG; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ACUTE DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL DIVISION; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INHIBITORS; FEMALE; HUMANS; INFLAMMATION; INTERFERON TYPE II; INTERLEUKIN-5; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED STRAINS; MULTIPLE SCLEROSIS; OXAZOLES; RATS; RATS, INBRED LEW; RECURRENCE; SPLEEN; SUBSTRATE SPECIFICITY; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034255695     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00265-4     Document Type: Article

References (52)

1. Abbas, A.K., Murphy, K.M., Sher, A., 1996. Functional diversity of helper T lymphocytes. Nature 383, 787-793.
2. 2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2Rα gene expression at multiple levels. J. Immunol. 148, 2845-2852.
3. Ando, D.G., Clayton, J., Kong, D., Urban, J.L., Sercarz, J.L., 1989. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell. Immunol. 124, 132-143.
4. Baron, J.L., Madri, J.A., Ruddle, N.H., Hashim, G., Janeway, Jr. C.A., 1993. Surface expression of α integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177, 57-68.
5. Beavo, J.A., Conti, M., Heaslip, R.J., 1994. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46, 399-405.
6. Betz, M., Fox, B. S., 1991. Prostaglandin E2 inhibits production of TH1 lymphokines but not TH2 lymphokines. J. Immunol. 146, 108-113.
7. Briggs, W.A., Wu, Q., Orgul, O., Choi, M., Scheel, P., Burdick, J., 1999. Lymphocyte suppression by rolipram with other immunosuppressive drugs. J. Clin. Pharmacol. 39, 794-799.
8. Cone, R.E., Cochrane, R., Lingenheld, E.G., Clark, R.B., 1996. Elevation of intracellular cAMP induces an anergic-like state in Th1 clones. Cell. Immunol. 173, 246-251.
9. Cua, D.J., Hinton, D.R., Stohlman, S.A., 1995. Self-antigen-mduced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice. J. Immunol. 155, 4052-4059.
10. Ekholm, D., Hemmer, B., Gao, G., Vergelli, M., Martin, R., Manganiello, V., 1997. Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein. J. Immunol. 159, 1520-1529.
11. Engels, P., Fichtel, K., Lübbert, H., 1994. Expression and regulation of human and rat phosphodiesterase type IV. FEBS Lett. 350, 291-295.
12. Essayan, D.M., Kagey-Sobotka, A., Lichtenstein, L.M., Huang, S.-K., 1997b. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 282, 505-512.
13. Essayan, D.M., Huang, S.-K., Kagey-Sobotka, A., Lichtenstein, L.M., 1997a. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J. Allergy Clin. Immunol. 99, 28-37.
14. Figueiredo, F., Uhing, R.J., Okonogi, K., Gettys, T.W., Johnson, S.P., Adams, D.O., Prpic, V., 1990. Activation of the cAMP cascade inhibits an early event involved in murine macrophage Ia expression. J. Biol. Chem. 265, 12317-12323.
15. Folcik, V.A., Smith, T., O'Bryant, S., Kawczak, J.A., Zhu, B., Sakurai, H., Kajiwara, A., Staddon, J.M., Glabinski, A., Chernosky, A.L., Tani, M., Johnson, J.M., Tuohy, V.K., Rubin, L.L., Ransohoff, R.M., 1999. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. J. Neuroimmunol. 97, 119-128.
16. Fujimoto, T., Sakoda, S., Fujimura, H., Yanagihara, T., 1999. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J. Neuroimmunol. 95, 35-42.
17. Genam, C.P., Roberts, T., Davis, R.L., Nguyen, M.-H., Uccelli, A., Faulds, D., Li, Y., Hedgepeth, J., Hauser, S.L., 1995. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA 92, 3601-3605.
18. Greten, T.F., Eigler, A., Sinha, B., Moeller, J., Endres, S., 1995. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide. Int. J. Immunopharmacol. 17, 605-610.
19. Ivaskiv, L.B., Glimcher, L.H., 1991. Repression of class II major histocompatibility complex genes by cyclic AMP is mediated by conserved promoter elements. J. Exp. Med. 174, 1583-1592.
20. Jenkins, M.K., Schwartz, R.H., 1987. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165, 302-319.
21. Jung, St., Zielasek, J., Köllner, G., Donhauser, T., Toyka, K., Hartung, K.-P., 1996. Preventive but not therapeutic application of rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 68, 1-11.
22. Kaye, J., Procelli, S., Tite, J., Jones, B., Janeway, J.A., 1983. Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells. J. Exp. Med. 158, 836-856.
23. + T cells while decreasing IL-2 release and NF-AT induction. Int. Immunol. 6, 1333-1343.
24. Lederer, J.A., Liou, J.S., Kim, S., Rice, N., Lichtman, A.H., 1996. Regulation of NF-κB activation in T helper 1 and T helper 2 cells. J. Immunol. 156, 56-63.
25. Lingk, D.S., Chan, M.A., Gelfand, E.W., 1990. Increased cyclic monophosphate levels block progression but not initiation of human T cell proliferation. J. Immunol. 145, 449-455.
26. Marcoz, P., Prigent, A.F., Lagarde, M., Nemoz, G., 1993. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Mol. Pharmacol. 44, 1027-1035.
27. Martenson, R.E., 1984. A useful model for multiple sclerosis. In: Alvord, Jr. E.C. (Ed.). Experimental Allergic Encephalomyelitis, Vol. 146. Alan Liss, New York, pp. 511-521.
28. Martin, R., McFarland, H.F., 1995. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit. Rev. Clin. Lab. Sci. 32, 121-182.
29. Martin, R., McFarland, H.F., McFarlin, D.E., 1992. Immunological aspects of demyelinating diseases. Ann. Rev. Immunol. 10, 153-187.
30. Mary, D., Aussel, C., Ferrua, B., Fehlmann, M., 1987. Regulation of interleukin 2 synthesis by cAMP in human T cells. J. Immunol. 139, 1179-1184.
31. Merrill, J.E., Kono, D.H., Clayton, J., Ando, D.G., Hinton, D.R., Hofman, F.M., 1992. Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental autoimmune encephalomyelitis in SJL and B10.PL mice. Proc. Natl. Acad. Sci. USA 89, 575-578.
32. Morandini, R., Ghanem, G., Protier-Lemarie, A., Robaye, B., Renaud, A., Boeynaems, J.M., 1996. Action of cAMP on expression and release of adhesion molecules in human endothelial cells. Am. J. Physiol. 270, H807-H816.
33. Munoz, E., Zubiaga, A.M., Merrow, M., Sauter, N.P., Huber, B.T., 1990. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor mediated activation. J. Exp. Med. 172, 95-103.
34. Navikas, V., Matusevicius, D., Söderström, M., Pirskanen, R., Fredrikson, S., Link, H., 1998. The phosphodiesterase IV inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-γ and TNF-α mRNA expressing blood mononuclear cells in patients with multiple sclerosis. Clin. Neuropharm. 21, 236-244.
35. Novak, T.J., Rothenberg, E.V., 1990. cAMP inhibits induction of interleukin-2 but not of interleukin-4 in T cells. Proc. Natl. Acad. Sci. USA 87, 9353-9357.
36. Olsson, T., 1995. Critical influences of the cytokine orchestration or the outcome of myelin antigen-specific autoimmunity in experimental autoimmune encephalomyelitis, multiple sclerosis. Immunol. Review 144, 245-268.
37. Ozawa, K., Suchanek, G., Breitschopf, H., Brack, W., Budka, H., Jellinger, K., Lassmann, H., 1994. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 117, 1311-1322.
38. Pette, M., Muraro, P.A., Pette, D.F., Dinter, H., McFarland, H.F., Martin, R., 1999. Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones. J. Neuroimmunol. 98, 147-156.
39. Phipps, R.P., Stein, S.H., Roper, R.L., 1991. A new view of prostaglandin E regulation of the immune response. Immunol. Today 12, 349-352.
40. Raine, C.S., Traugott, U., 1984. Immunopathology of the lesion in multiple sclerosis and chronic relapsing EAE. In: Vandenbark, A.A., Raus, J.C.M. (Eds.), Immunoregulatory Processes in Experimental Allergic Encephalomyelitis and Multiple Sclerosis. Elsevier, Amsterdam, pp. 151-212.
41. Rott, O., Cash, E., Fleischer, B., 1993. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 23, 1745-1751.
42. Schmidt, J., Hatzelmann, A., Fleissner, S., Heimann-Weitschat, I., Lindstaedt, R., Szelenyi, I., 1995. Effect of phosphodiesterase inhibition on IL-4 and IL-5 production of the murine Th2-type T cell clone D10.G4.1. Immunopharmacology 30, 191-198.
43. + T cell clones in the rat. Cloning methodology and interferon-γ secretion. J. Immunol. Methods 121, 185-196.
44. Sommer, N., Martin, R., McFarland, H.F., Quigley, L., Canella, B., Raince, C.S., Scott, D.E., Löschmann, P.A., Racke, M.K., 1997. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J. Neuroimmunol. 79, 54-61.
45. Sommer, N., Löschmann, P.A., Northoff, G.H., Weller, M., Steinbrecher, A., Steinbach, J.P., Lichtenfels, R., Meyermann, R., Riethmüller, A., Fontana, A., Dichgans, J., Martin, R., 1995. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med. 1, 244-248.
46. Tony, H.-P, Phillips, N.E., Parker, D.C., 1985. Role of membrane immunoglobulin (Ig) crosslinking in membrane Ig-mediated, major histocompatibility-restricted T cell-B cell cooperation. J. Exp. Med. 162, 1695-1708.
47. Traugott, U., Lebon, P, 1988. Interferon-gamma and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions. J. Neurol. Sci. 84, 257-262.
48. van der Veen, R., Stohlman, S.A., 1993. Encephalitogenic Th1 cells are inhibited by Th2 cells with related peptide specificity: roles of interleukin (IL)-4 and -10. J. Neuroimmunol. 48, 213-220.
49. Traugott, U., Reinherz, E.L., Raine, C.S., 1983. Multiple Sclerosis: distribution of T-cell subsets within active chronic lesions. Science 219, 308-310.
50. Verghese, M.W., McConnell, R.T., Strickland, A.B., 1995. Differential regulation of human monocyte-derived TNFα and IL-1β by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J. Pharmacol. Exp. Ther. 272, 1313-1320.
51. Woodroofe, M.N., Cuzner, M.L., 1993. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 5, 583-588.
52. Zeller, E., Stief, H.J., Pflug, B., Sastre-y-Hernandez, M., 1984. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 17, 188-190.